Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer
Open Access
- 1 February 2019
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 5 (2) , 236-242
Abstract
Colorectal cancer ranks third in the number of diagnoses and deaths in the United States, with 135 430 new diagnoses and 50 260 deaths estimated for 2017.1 The price of antineoplastic drugs represents a large and growing source of high health care costs,2 and American drug prices, already the highest in the world, will increase by 50% between 2010 and 2020.2,3 Most new cancer drugs now cost more than $100 000 per year, with certain regimens exceeding $1 000 000 per year.2 Despite higher drug costs, benefits have lagged, and average cost per life-year gained have increased from $54 000 per life-year in 1995 to $207 000 per life-year in 2013.3Keywords
This publication has 19 references indexed in Scilit:
- Cancer care cost trends in the United States: 1998 to 2012Cancer, 2016
- In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer DrugsMayo Clinic Proceedings, 2015
- Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an OncologistAmerican Society of Clinical Oncology Educational Book, 2015
- Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer GroupThe Lancet, 2015
- First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness AnalysisJournal of Clinical Oncology, 2015
- Indication-Specific Pricing for Cancer DrugsJAMA, 2014
- Addressing the American Health-Care Cost Crisis: Role of the Oncology CommunityJNCI: Journal of the National Cancer Institute, 2013
- The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML expertsBlood, 2013
- Cancer treatment cost in the United StatesCancer, 2010
- A convenient approximation of life expectancy (the “DEALE”)The American Journal of Medicine, 1982